0000899243-21-025980.txt : 20210625 0000899243-21-025980.hdr.sgml : 20210625 20210625170057 ACCESSION NUMBER: 0000899243-21-025980 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210412 FILED AS OF DATE: 20210625 DATE AS OF CHANGE: 20210625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blackwell Kimberly CENTRAL INDEX KEY: 0001816465 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 211048795 MAIL ADDRESS: STREET 1: C/O ZENTALIS PHARMACEUTICALS, LLC STREET 2: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-12 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001816465 Blackwell Kimberly MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210 1 0 0 0 Stock Option (Right to Buy) 6.14 2021-04-12 4 A 0 7081 0.00 A 2031-04-12 Common Stock 7081 7081 D Stock Option (Right to Buy) 19.00 2021-06-23 4 A 0 47132 0.00 A 2031-06-22 Common Stock 47132 47132 D On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021. /s/ Ajim Tamboli, Attorney-in-Fact 2021-06-25